Mankind Pharma to Invest EUR 45Mn in Subsidiary, Acquire ACTx

Mankind Pharma Limited announced an additional investment of up to EUR 45 million in its wholly-owned subsidiary, Mankind Pharma (Netherlands) B.V., increasing the total investment limit to EUR 50 million. This investment will be used to acquire a 70% stake in Armed Cell Therapeutics B.V. (ACTx), a Belgium-based biotechnology company focused on CAR-T therapies for cancer. This strategic move aims to build Mankind Pharma's global innovation-led pharmaceutical business. The acquisition is part of the company's long-term strategy.